Search results for "Law"

showing 10 items of 23812 documents

Renewable energies, business models and local growth

2018

Abstract Energy is one of the driving factors of the world economy: energy consumption is closely linked to quality of life and environmental impact. Reducing the use of fossil fuels, curtailing greenhouse gas emissions, and cutting energy dependence from traditional energy producing countries are the cornerstones of European policies for safe, competitive, sustainable, and renewable energy. In addition, the pressing need to provide new and diversified opportunities for supplementary income for the agricultural sector has fueled the desire to engage rural areas in this process. Biogas, derived from the anaerobic digestion of biomass, is one of the renewable energy sources that has been very…

0301 basic medicineNatural resource economics020209 energyGeography Planning and Development02 engineering and technologyGrowthManagement Monitoring Policy and Law03 medical and health sciencesBiogasBioenergySettore AGR/01 - Economia Ed Estimo Rurale0202 electrical engineering electronic engineering information engineeringTerritoryNature and Landscape ConservationDriving factorsbusiness.industry030111 toxicologyFossil fuelInternal rate of returnAgricultureForestryEnergy consumptionRenewable energyGreenhouse gasRenewable resourceBusiness
researchProduct

2019

During lytic herpes simplex virus 1 (HSV-1) infection, the expansion of the viral replication compartments leads to an enrichment of the host chromatin in the peripheral nucleoplasm. We have shown previously that HSV-1 infection induces the formation of channels through the compacted peripheral chromatin. Here, we used three-dimensional confocal and expansion microscopy, soft X-ray tomography, electron microscopy, and random walk simulations to analyze the kinetics of host chromatin redistribution and capsid localization relative to their egress site at the nuclear envelope. Our data demonstrated a gradual increase in chromatin marginalization, and the kinetics of chromatin smoothening arou…

0301 basic medicineNucleoplasm030102 biochemistry & molecular biologyChemistryvirusesConfocalmedicine.disease_cause3. Good healthlaw.inventionChromatinCell biology03 medical and health sciences030104 developmental biologyInfectious DiseasesHerpes simplex virusCapsidLytic cycleViral replicationlawVirologymedicineElectron microscopeViruses
researchProduct

Multiplex Detection of Aspergillus Species

2016

Multiplex real-time polymerase chain reaction (PCR) provides a fast and accurate DNA-based tool for the simultaneous amplification of more than one target sequence in a single reaction. Here a duplex real-time PCR assay is described for the simultaneous detection of Aspergillus carbonarius and members of the Aspergillus niger aggregate, which are the main responsible species for ochratoxin A (OTA) contamination in grapes. This single tube reaction targets the beta-ketosynthase and the acyl transferase domains of the polyketide synthase of A. carbonarius and the A. niger aggregate, respectively.Besides, a rapid and efficient fungi DNA extraction procedure is described suitable to be applied …

0301 basic medicineOchratoxin AChromatographybiologyfungi030106 microbiologyAspergillus nigerfood and beveragesbiology.organism_classificationDNA extractionlaw.invention03 medical and health scienceschemistry.chemical_compound030104 developmental biologyReal-time polymerase chain reactionchemistrylawPolyketide synthaseMultiplex polymerase chain reactionbiology.proteinMultiplexPolymerase chain reaction
researchProduct

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Ju…

2017

Abstract Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy. Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The prim…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsPhases of clinical researchIpilimumabDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansAdverse effectAgedbusiness.industryCancerMiddle AgedInterim analysismedicine.diseaseIpilimumabSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleEsophagogastric Junctionbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.

2018

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. Patients and Methods: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. Results: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months wit…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSingle CenterGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorTargeted therapylaw.invention03 medical and health sciences0302 clinical medicineRisk groupsRandomized controlled trialRenal cell carcinomalawRisk FactorsInternal medicineGermanymedicineOverall survivalHumansMolecular Targeted TherapyNeoplasm MetastasisSurvival rateCarcinoma Renal CellProtein Kinase InhibitorsAgedRandomized Controlled Trials as TopicRetrospective StudiesPharmacologybusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisFemalebusinessResearch ArticleIn vivo (Athens, Greece)
researchProduct

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review

2020

Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment of painful bone metastases, however only a limited number of metastases can be irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC through a systematic review. Methods: Systematic review including all prospective articles published between 01-1994 and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: nonradiation based trials evaluating CIBP early pain relief options (initially defined as pain score evaluated within two weeks, because of no randomized trials, …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPain reliefcancer induced bone painCochrane Librarylcsh:RC254-282DISEASEpain relieflaw.inventionPALLIATIVE RADIOTHERAPY03 medical and health sciences0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beingbone metastasessystematic reviewlawQUALITY-OF-LIFEInternal medicinemedicineLung cancerBone painIBANDRONATEbisphosphonatesnon-small cell lung cancerDENOSUMABbusiness.industryGold standardCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensEFFICACYRadiation therapy1ST-LINE TREATMENT030104 developmental biologyMETASTASESOncology030220 oncology & carcinogenesisZOLEDRONIC ACIDmedicine.symptombusinessFrontiers in Oncology
researchProduct

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Mult…

2017

Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cycles. The primary end point of the study was to improve disease-fre…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMulticenter trialPancreatic cancermedicineClinical endpointChemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good healthClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisErlotinibbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial.

2017

Purpose To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. Methods and Materials The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence…

0301 basic medicineOncologyCancer Researchmedicine.medical_treatmentDocetaxelMastectomy Segmentallaw.invention0302 clinical medicineRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsAnthracyclinesMastectomyRadiationHazard ratioCarcinoma Ductal BreastMiddle Agedmedicine.anatomical_structureEditorialOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsBreast Neoplasms03 medical and health sciencesYoung AdultBreast cancerInternal medicinemedicineConfidence IntervalsHumansRadiology Nuclear Medicine and imagingCyclophosphamideAgedNeoplasm StagingPostoperative Carebusiness.industryCancermedicine.diseaseClinical trialAxilla030104 developmental biologyDoxorubicinAxillaLymph Node ExcisionLymph NodesbusinessInternational journal of radiation oncology, biology, physics
researchProduct

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas

2021

Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas…

0301 basic medicineOncologyCàncer en els infantsmedicine.medical_specialtyprecision medicinetargeted drugslcsh:MedicineMedicine (miscellaneous)Articlepaediatric sarcomasclinical translationDNA sequencinglaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGene panelmedicineOssos MalaltiesPolymerase chain reactionPaediatric patientsBiological studiesbusiness.industrylcsh:RHistopathological analysisPrecision medicine030104 developmental biology030220 oncology & carcinogenesisCohortnext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

2017

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreat…

0301 basic medicineOncologyHER2 positivereal-worldmedicine.medical_specialtyHER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-worldHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1; OncologyT-DM1Previous pertuzumabHER2 positive; metastatic breast cancer; previous pertuzumab; real-world; T-DM1; oncologyECOG Performance Statuslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialSettore MED/04 - PATOLOGIA GENERALElawInternal medicineMedicineUnivariate analysisSettore MED/06 - ONCOLOGIA MEDICAbusiness.industryCancerprevious pertuzumabmedicine.diseaseMetastatic breast cancerMetastatic breast cancerHER2 positive; Metastatic breast cancer; Previous pertuzumab; Real-world; T-DM1Log-rank testtrastuzumab030104 developmental biologyOncologychemistryReal-worldTrastuzumab emtansine030220 oncology & carcinogenesisHER2 positive Metastatic breast cancer Previous pertuzumab Real-world T-DM1 Oncologymetastatic breast cancerPertuzumabbusinessmedicine.drugResearch Paper
researchProduct